Celltrion, WuXi XDC to develop new antibody-drug conjugates
Jeong Min Nam
Jan 24, 2024 (Gmt+09:00)
South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC).
In December last year, Celltrion inked the contract development and manufacturing services (CDMO) with WuXi XDC to work on the linker and payload synthesis process.
WuXi XDC, formed by WuXi Biologics and WuXi STA, provides specialized contract research, development, and manufacturing services (CRDMO) focusing on ADCs and bioconjugates.
WuXi XDC completed a new plant in September last year. This production facility facilitates comprehensive production capabilities from ADC therapeutic development to the manufacturing of raw materials and final pharmaceutical products.
The enhanced partnership with WuXi XDC is expected to enable Celltrion to expand its ADC pipelines. The company is developing six ADC lines.
It aims to expedite the development of its multiple ADC drug pipelines by leveraging its expertise in its technology in collaboration with WuXi XDC.